David Mott news from FierceBiotech
News
MedImmune's Mott starts new career in VC
MedImmune's ex-CEO, David Mott, is starting a new career as a venture capitalist. He's been named a general partner at New Enterprise Associates, a busy investor in the biotech field. Mott says he... Read more...
MedImmune’s Mott heads for the exit
David Mott, the CEO of MedImmune who led his company through a $15.6 billion buyout by AstraZeneca, is leaving the company a year after the deal closed. Mott says he's leaving for personal reasons... Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
